Immune-Marker Platform for Patients With Advanced Lung Cancer

This study is for adults aged 18 or over who have advanced non-small cell lung cancer (NSCLC) that can't be cured. You must not have certain common genetic changes in your cancer that can be targeted with other specific drugs. Also, your cancer's PD-L1 expression (a marker related to how immunotherapy works) must be less than 50%.

There are two groups in the study. If you're in Cohort A, you haven't started treatment for your advanced lung cancer yet. If you're in Cohort B, you've already had first-line immunochemotherapy and your cancer has progressed.

You cannot take part if a doctor thinks getting an extra tumour sample would be too risky for you, or if you can't understand what the study involves. Certain issues like drug or alcohol misuse, or other medical/mental health conditions that might stop you from taking part safely, would also prevent you from joining.

If you decide to take part in this study, you'll be asked to provide small samples of your tumour tissue. This will usually involve a procedure called a biopsy. You would have a biopsy before you start your immunochemotherapy, another one about six weeks after starting treatment, and potentially another if your cancer progresses or your treatment changes. These samples will be analysed by researchers in a laboratory to look for immune and genetic markers. You'll also be asked to share information about your treatment response and how your illness is progressing, which the researchers will link to the findings from your tumour samples. This study does not involve taking any new medications or treatments; it's about studying the treatments you are already receiving.